Back to List View Graph View

Anti-PD-1 therapy

Anti-PD-1 therapy is a class of cancer immunotherapy in which monoclonal antibodies — nivolumab and pembrolizumab among them — block the Programmed cell death 1 (PD-1) receptor on T cells, interrupting its engagement by the ligand CD274 molecule.

Where the papers sit

21 papers from the last 6 months study Anti-PD-1 therapy directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 4 observational · 4 human data · 8 preclinical · 5 unclassified

Themes 4 themes

  • Immune Resistance Mechanisms

    Tumor immune resistance is increasingly traced to suppressive myeloid niches, altered metabolism and dysfunctional CD8-positive T cells. NNMT, ALDH9A1-carnitine signaling, SPP1, PD-L1/mTOR regulation and ferroptosis-resistant myeloid cells recur as actionable mechanisms. PET tracking and single-cell multiomics are sharpening response assessment. In situ vaccination and pathway-targeted combinations aim to restore anti-PD-1 sensitivity.

    8 papers · 38.1%

  • Metabolic Resistance in HCC

    Anti-PD-1 resistance in hepatocellular carcinoma is being framed as a metabolic and microenvironmental problem. ChREBP/PKLR-driven lactate, lipid abnormalities and mast-cell CCL17/CCR4 signaling can suppress cytotoxic T-cell activity. Extracellular vesicles and tumor-selective CD28 siRNA lipid nanoparticles are being targeted to remodel these barriers. Multimodal profiling of neoadjuvant nivolumab aims to identify combinations that overcome resistance.

    6 papers · 28.6%

  • Checkpoint Therapy and Tregs

    Checkpoint treatment is moving toward perioperative combinations and direct control of regulatory T cells. Neoadjuvant PD-1 blockade with oncolytic virus shows durable benefit in acral melanoma, while STING signaling remains linked to resistance. IKZF2/IKZF4 degraders offer a pharmacologic route to weaken Treg programs. Clinical studies also expose trade-offs, including increased opioid use after surgery and variable adjuvant survival outcomes.

    4 papers · 19%

  • Others — PD-1 Toxicity and Tumor Escape

    PD-1 treatment produces both endocrine toxicity and tumor immune escape, but this cluster has no single direction. Pituitary-axis dysfunction and broader immune-related adverse events are being characterized through proteomic and metabolomic changes. Lipid, tryptophan and SNRPA-associated signals appear among candidate biomarkers. Separately, CD155 links cervical-cancer immunotype to epithelial-directed therapy beyond checkpoint blockade.

    3 papers · 14.3%

Papers

The 21 papers from the last 6 months that study Anti-PD-1 therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Immune Resistance Mechanisms (8)
  1. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  2. [68Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8+ T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 27 Aug 2026 PMID 42660635
  3. Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574617
  4. A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
  5. Ferroptosis-resistant myeloid niche shapes tumor natural evolution in glioblastoma. Cancer letters · 9 Jul 2026 PMID 42425190
  6. Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment. Oncogene · 17 Jun 2026 PMID 42310095
  7. Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer. Cancer letters · 30 May 2026 PMID 42217559
  8. PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis. RMD open · 20 May 2026 PMID 42161414
Metabolic Resistance in HCC (6)
  1. Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment. Journal of biochemical and molecular toxicology · 20 Oct 2026 PMID 42900017
  2. Targeting the ChREBP/PKLR-lactate axis via Huachansu tablets restores CD8⁺T cell immunity in MASH-HCC. Pharmacological research · 14 Sept 2026 PMID 42735733
  3. Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. Annals of medicine · 25 Aug 2026 PMID 42638413
  4. Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
  5. Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma. Molecular cancer · 2 Jun 2026 PMID 42226281
  6. Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. Signal transduction and targeted therapy · 27 May 2026 PMID 42204141
Checkpoint Therapy and Tregs (4)
  1. Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors. Journal of medicinal chemistry · 1 Sept 2026 PMID 42677819
  2. When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction. Breast cancer research and treatment · 12 Aug 2026 PMID 42584510
  3. Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372635
  4. Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy. Experimental hematology & oncology · 2 Jun 2026 PMID 42226303
Others — PD-1 Toxicity and Tumor Escape (3)
  1. Proteomic and Metabolomic Analysis of Immune-Related Adverse Events in Patients Treated with PD-1 Inhibitors. Journal of proteome research · 4 Sept 2026 PMID 42695906
  2. Multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy in an esophageal cancer patient: Case report. Medicine · 23 May 2026 PMID 42175425
  3. CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. Journal for immunotherapy of cancer · 20 May 2026 PMID 42161400

By study type

Observational studies and case reports (4)
  1. Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. Annals of medicine · 25 Aug 2026 PMID 42638413
  2. When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction. Breast cancer research and treatment · 12 Aug 2026 PMID 42584510
  3. Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372635
  4. Multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy in an esophageal cancer patient: Case report. Medicine · 23 May 2026 PMID 42175425
Human data, design not indexed (4)
  1. Proteomic and Metabolomic Analysis of Immune-Related Adverse Events in Patients Treated with PD-1 Inhibitors. Journal of proteome research · 4 Sept 2026 PMID 42695906
  2. [68Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8+ T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 27 Aug 2026 PMID 42660635
  3. PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis. RMD open · 20 May 2026 PMID 42161414
  4. CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. Journal for immunotherapy of cancer · 20 May 2026 PMID 42161400
Preclinical: animal, cell and lab studies (8)
  1. Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment. Journal of biochemical and molecular toxicology · 20 Oct 2026 PMID 42900017
  2. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  3. Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors. Journal of medicinal chemistry · 1 Sept 2026 PMID 42677819
  4. Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574617
  5. A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
  6. Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment. Oncogene · 17 Jun 2026 PMID 42310095
  7. Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer. Cancer letters · 30 May 2026 PMID 42217559
  8. Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. Signal transduction and targeted therapy · 27 May 2026 PMID 42204141
Unclassified: not yet indexed with MeSH (5)
  1. Targeting the ChREBP/PKLR-lactate axis via Huachansu tablets restores CD8⁺T cell immunity in MASH-HCC. Pharmacological research · 14 Sept 2026 PMID 42735733
  2. Ferroptosis-resistant myeloid niche shapes tumor natural evolution in glioblastoma. Cancer letters · 9 Jul 2026 PMID 42425190
  3. Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
  4. Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy. Experimental hematology & oncology · 2 Jun 2026 PMID 42226303
  5. Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma. Molecular cancer · 2 Jun 2026 PMID 42226281